Nevertheless, antiplatelet agents alone and in combination with vitamin K antagonists (VKAs) remain a mainstay in prevention of arterial thrombosis in APS, despite controversy around the impact of typical atherosclerotic vascular disease and its risk factors on therapeutic strategies in the presence of IgG and/or IgM aPL at significant titers. Here, FASLG is linked to Arterial thrombosis.